Effect of low-molecular-weight heparins on anti-Xa peak levels and adverse reactions in Chinese patients with recurrent spontaneous abortion: a single-center, observational study

To compare three commonly used low-molecular-weight heparins (LWMHs) in the treatment of recurrent spontaneous abortion (RSA) by evaluating the anti-Xa peak levels and adverse reactions. In this single-center, observational study, we enrolled 310 patients with RSA in whom anti-Xa levels were measure...

Full description

Saved in:
Bibliographic Details
Published in:BMC pregnancy and childbirth 2021-10, Vol.21 (1), p.683-683, Article 683
Main Authors: Bai, Wenxin, Zhang, Xinyang, Sun, Si, Wang, Qiaohong, Li, Congcong, Zhang, Xiaoxin, Zhao, Aimin
Format: Article
Language:English
Subjects:
Abortion, Habitual - drug therapy
Adult
Anticoagulants
Anticoagulants - adverse effects
Anticoagulants - pharmacology
Anticoagulants - therapeutic use
Asians
Blood Coagulation - drug effects
Blood platelets
Blood tests
China - epidemiology
Dalteparin - administration & dosage
Drug Hypersensitivity - complications
Drug-Related Side Effects and Adverse Reactions - complications
Enoxaparin - administration & dosage
Factor Xa Inhibitors - blood
Female
Heparin, Low-Molecular-Weight - adverse effects
Heparin, Low-Molecular-Weight - pharmacology
Heparin, Low-Molecular-Weight - therapeutic use
Humans
Incidence
Laboratories
levels
adverse reaction
Liver
Low molecular weight heparin
Miscarriage
Nadroparin - administration & dosage
Observational studies
Osteoporosis
Patients
Peak anti-Xa
Pharmacokinetics
Plasma
Pregnancy
Recurrent spontaneous abortion
Thrombocytopenia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To compare three commonly used low-molecular-weight heparins (LWMHs) in the treatment of recurrent spontaneous abortion (RSA) by evaluating the anti-Xa peak levels and adverse reactions. In this single-center, observational study, we enrolled 310 patients with RSA in whom anti-Xa levels were measured during pregnancy. Patients were divided into three groups according to the LMWH they used: the nadroparin group, enoxaparin group and dalteparin group. We compared the peak anti-Xa levels and the coagulation status of each group, and analyzed the incidence of adverse reactions, including local allergy, liver and renal dysfunction, and the impact on platelet. Patients in the enoxaparin group had a higher anti-Xa peak level than those in the nadroparin group (0.80 ± 0.22 IU/ml vs. 0.61 ± 0.24 IU/ml; P 
ISSN:1471-2393
1471-2393
DOI:10.1186/s12884-021-04161-1